Regeneron Showcases Updated P-I/II (LINKER-MM1) Study Data of Linvoseltamab for Treating R/R Multiple Myeloma at EHA 2024
Shots:
- The 14mos. median follow-up (n=117), published in the Journal of Clinical Oncology, showed ORR of 71% (with CR: >50% & VGPR: 63%); mDoR of 29mos. in all responders; mPFS not attained & mOS of 31mos. for all patients. In age ≥75yrs. CR: 55%, 48% in high cytogenetic risk, 45% in Black/African Americans & 28% in plasmacytomas was observed
- The retrospective study of P-II (LINKER-MM1) trial patients (n=105) vs real-world external control patients (n=101) on SoC showed ORR of 70% vs 32%, mPFS of 20mos. vs 3mos. & mOS not attained vs 12mos. Data was presented at EHA 2024
- The P-III (LINKER-MM3) confirmatory study of linvoseltamab for RRMM is underway. Moreover, linvoseltamab has received the FDA’s FTD & Priority Review for the same (PDUFA: Aug 22, 2024) & is also under the EMA’s review
Ref: Regeneron | Image: Regeneron
Related News:- Regeneron Reports the Acceptance of its MAA by the EMA for Linvoseltamab to Treat Multiple Myeloma (MM)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
